🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
7.10
+0.05 (0.71%)
At close: Nov 18, 2026, 4:00 PM EST
7.10
0.00 (-0.07%)
After-hours: Nov 18, 2026, 7:30 PM EST
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 10, 2026

Summary

AASLD data supported HBV reservoir editing, with a 0.4 mg/kg three-dose phase II regimen and results expected to begin rolling in 2H 2027. DMD initial biopsy data are expected in 2027, with financing extending runway through Q4 2029.

Debjit Chattopadhyay
Analyst, Guggenheim

All right. Good morning, and thank you for joining Guggenheim's third annual Healthcare Innovation Conference. I am Debjit, one of the therapeutic analysts, and it's my privilege to welcome our next presenting company, Precision. Joining from Precision are CEO Michael Amoroso and Chief Scientific Officer Cassie Gorsuch. Thank you both for making time for us. You guys are on a roll right now. Let's start with the most recent data update that happened just over the weekend, and take us through the HBV landscape as to how you see it evolve.

Michael Amoroso
CEO, Precision

Sure. First of all, good morning, everybody, and Debjit, good to see you. We are on a roll because of science, real sound science for people like Cassie. This was her baby, so I'm going to let her talk to you about what we just presented at the late-breaking oral presentation this last weekend in Denver at AASLD. Cassie?

Cassie Gorsuch
Chief Scientific Officer, Precision

Sure. Yeah, thank you all for being here, and thank you for the question, Debjit. Precision, we're a gene editing company. That's the central thesis behind all of our programs. Our hepatitis B program is now moving to a phase II study, so that was really the excitement to see that this program continues to advance. What we showed was that a first-in-class, really the only of its kind, gene editing approach that is aimed at eliminating cccDNA in the liver now has demonstrated a very robust data package with consistent loss of our biomarker, pgRNA, really important biomarker that I'm sure we'll get into, as well as biopsy evidence of proof of mechanism of eliminating cccDNA in the liver, leading to durable and sustained consistent pgRNA loss across now a more robust dataset.

We've selected our go-forward dose for our phase II study of 0.4 mg per kilogram on the basis of both safety and efficacy. That was really an exciting opportunity to share the data with the field and show the progression of the program.

Debjit Chattopadhyay
Analyst, Guggenheim

Got it. Let's unpack that a little bit on the pgRNA side and on the reservoir, given the 1 to 1.5 log decrease in cccDNA. There seems to be still a reservoir left, but the pgRNA is undetectable. Can you sort of help us understand that?

Michael Amoroso
CEO, Precision

Great question.

Cassie Gorsuch
Chief Scientific Officer, Precision

Yeah, happy to. pgRNA is a blood biomarker. We know it's a good biomarker. It's been published to be associated with, if you have undetectable pgRNA, better chances of sustained off-therapy cure. We know it is a valuable biomarker, and we like it for our specific mechanism because pgRNA only comes from cccDNA. PBGENE-HBV is designed to eliminate the viral reservoir in the liver, cccDNA, and that's the source of pgRNA. The other upside of pgRNA, the reason it's a great biomarker, is that pgRNA is the source of HBV DNA. HBV DNA is the circulating infectious particles that lead to transmission between people, and importantly, it's the regulatory endpoint. Undetectable HBV DNA off treatment for at least six months is required by FDA in finite course treatment approaches for hep B like ours is.

pgRNA sits in this really important middle spot between cccDNA and HBV DNA, and it's detectable while patients are on nukes. It's our biomarker that we follow. Now, cccDNA in the liver, to your question about the biopsies, what we're measuring in our biopsies is actually beyond the DNA level. We're looking at RNA transcripts in the biopsies. The reason we chose to do that is it allows a deeper, more sensitive analysis of what's going on in the liver. DNA, cccDNA, is very hard to detect in e-antigen-negative patients who've been nuke suppressed for many years. Looking at the transcript level actually allows you to look deeper, see more than you can at the DNA level. We're looking at transcripts.

What we see in our two biopsies is proof of principle, proof that PBGENE-HBV gets to the liver and eliminates cccDNA, driving, as you said, a tenfold or one log and one and a half log respectively in our two biopsy patients, decreases in cccDNA-derived transcripts. We know even in the absence of pgRNA blood biomarker that you can see cccDNA transcripts in the liver, and you can see further reduction. What does that mean if we bring it up a level? What it means is that there is value in treating patients who are pgRNA undetectable because you can see cccDNA reduction in the liver. You can still see cccDNA elimination beyond what you can see in the blood. However, we know that the blood biomarker correlates with improved odds of stopping nukes.

What we take all of that to mean is that in the phase II study, our goal is to provide a finite course of treatment for patients, three administrations, 0.4 mg per kg on a Q8 week schedule. Even if the blood biomarker is undetectable, we know that there's still benefit of driving deeper cccDNA reductions in the liver, and that's the plan for the phase II study. We know that that biomarker correlates with improved odds of stopping nukes.

Michael Amoroso
CEO, Precision

I'll just make one small point there. If you look at our data on the swimmer's plot, the very important data where we talked about if you go green, that's a good thing, and we stay undetectable after you've been dosed with PBGENE-HBV. To Cassie's point, the go-forward dose will be 0.4 mg per kg, eight weeks apart, three times. We didn't have any patient that needed more than two doses, Debjit, to go undetectable, but we know the liver could still be even more sensitive, the tissue, and have some small amounts of cccDNA, so we make that third administration to make sure we give the patient best chance of cure once you stop all therapies.

Debjit Chattopadhyay
Analyst, Guggenheim

Another point of contention or debate really is the difference between a viral cure and a functional cure. Could you sort of walk us through where you land up on that? What's more important here?

Michael Amoroso
CEO, Precision

I am going to have you take us through, Cassie. I am just going to make one point. Debjit, what he just said is profound. The fact that one AASLD ago, we only talked about one pathway that existed through the FDA, functional cure, which is better than nothing, and it is a suppression endpoint, but HCC rates are still on the rise. You want to extinguish this virus permanently, all therapies. Cassie, with that, now that we have some tools to focus on that, I think it is great that we are talking about both pathways that exist already in the FDA guidance. Cassie?

Cassie Gorsuch
Chief Scientific Officer, Precision

Sure. I think maybe to start, just to elaborate on what Michael just said, there are two paths through FDA. Both of them require HBV DNA undetectable for at least six months off all therapies, and then functional cure layers in S-antigen. I think what is important here is if we can take a step back and think about what is the goal, what should be the goal in hepatitis B treatment? If you go back in the literature, beyond when we became this idea of suppressing S, if you go before that, the field has always agreed that cccDNA elimination is really the ideal therapeutic strategy. That is in the published literature many, many different places. It is also widely accepted that if you eliminate cccDNA, you will cure hepatitis B. The challenge is we never had a tool, a clinical modality that could actually do that.

We took different approaches to try to control the infection, to try to suppress viral proteins like S-antigen, with the goal of achieving immune control of the viral infection. But the goal for a viral infection should really be to cure the viral infection, and the way to do that is cccDNA elimination. That is what we are aimed at doing, is eliminating cccDNA, providing a viral cure to patients. No chance of viral relapse in the future because cccDNA and their viral infection is gone.

Debjit Chattopadhyay
Analyst, Guggenheim

How do you think S-antigen is going to evolve over time? Do you expect it to plateau? Do you expect it to continue dropping?

Cassie Gorsuch
Chief Scientific Officer, Precision

Yeah. With our mechanism, maybe I will take a step back, not our mechanism, just basic virology, biology for a second. S-antigen comes from both cccDNA and integrated DNA. Now, cccDNA makes new infectious particles, integrated DNA does not. The S-antigen that comes from the two is asymmetrically more important to get the cccDNA and get the S-antigen that is coming from cccDNA. When you think about our mechanism of eliminating cccDNA, you do expect some amount of S reduction. Now, every patient, the ratio of the S that comes from cccDNA versus integrated DNA, that is going to be different in every individual. There is not a set threshold by which you would expect to see S come down. It depends on how much S is coming from cccDNA in that patient.

But you would expect to see reductions, and it should be stable over time after treatment with PBGENE. That is what we see. We see a 40%-60% reduction in S-antigen that is stable in all of our patients. Now, over many, many years, will that S-antigen continue to decline because of hepatocyte turnover and loss of integrated DNA? Maybe. I think we will need to see how that bears out in the data. There is evidence that integrants decrease over time.

Michael Amoroso
CEO, Precision

Debjit, I would just add one thing to your question of where do we see it going. I think S is an absolute, it is an indiscriminate, it is a non-specific blood biomarker. All patients have it, and it is important to track longitudinally with treatment. I think that never goes away. I think how we have thought about S now gets actually deeper. You got to think about what source it is coming from. We have never been able to delineate that till now, and I am saying the S that comes from cccDNA, the only replication-competent source in the body for more virus, is asymmetrically more important. All viral transcripts and all viral proteins coming from cccDNA have to be gone. You must eliminate to get the cure. I think S will be always observed, it being the end-all be-all.

I think what ceases to exist going forward on new modalities, I do not think we are going to look to get S to undetectable and expect the body to turn on and get rid of the virus, because we have done a great job in 50 years at that, but we have done nothing about curing the virus. I think you will track S as a valuable treatment biomarker, but I think having therapies that target S only and praying for immunology, I think that ends. I think you will start to see more people targeting at the DNA level, the actual virus reservoir versus the RNA or the downstream protein level. I think that is what will change going forward.

Debjit Chattopadhyay
Analyst, Guggenheim

Yeah, I think the problem, as people try and understand this better, everybody has been taught to think about S-antigen.

Michael Amoroso
CEO, Precision

Yes.

Debjit Chattopadhyay
Analyst, Guggenheim

Now you're introducing a different paradigm here, which takes time to evolve or maybe understood properly.

Michael Amoroso
CEO, Precision

Sure.

Debjit Chattopadhyay
Analyst, Guggenheim

There was one patient who had positive S-antigen. What do we make of that? Or was that patient unique?

Cassie Gorsuch
Chief Scientific Officer, Precision

Oh, I think you may be talking about first e-antigen positive.

Debjit Chattopadhyay
Analyst, Guggenheim

Yeah .

Cassie Gorsuch
Chief Scientific Officer, Precision

Yes. Okay. E-antigen is a marker, it's a viral protein that gets made, and it's present in early infected patients. In the natural course of hepatitis B individuals, when people are first infected, they're all e-antigen positive, and then over time shift to e-antigen negative. What we know about those e-positives is that they have two to three logs higher cccDNA levels in their liver, they have more infected hepatocytes, and they have more pgRNA in the blood. You can see in our data that our first e-antigen positive patient had nearly 6,000 copies of pgRNA in the blood compared to, at most, a couple hundred in the e-antigen negative patients. This is an important population because they're difficult to treat because of the high burden of cccDNA, the high viral burden, and they have this higher cccDNA reservoir in their liver.

We were really thrilled that when we moved into this population, the first patient that we dosed at 0.4 mg per kg demonstrated a complete loss of detectable pgRNA in the blood. That tells you, that's at our go-forward dose of 0.4 mg, by the way, and what that tells you is that that dose level is sufficient to achieve the biodistribution across the liver to get to all those infected hepatocytes in an e-positive patient, where the task is harder, and it is sufficient to drive potent cccDNA elimination even under higher viral burden situation. I think that that data, super exciting data, I think it's been hugely impactful for all of the KOLs that we've talked with, our investigators, and ourselves, that the 0.4 mg per kg is the right dose for our phase II study.

Michael Amoroso
CEO, Precision

Yeah, this is the first time I think you can see a regardless of viral burden, because we're not focusing on masking or suppressing downstream. We're going at the source of the virus, at the DNA level. You're seeing, regardless of amount of virus, a ubiquitous treatment effect. That's profound because we leave no patient behind.

Debjit Chattopadhyay
Analyst, Guggenheim

Hypotension was an issue previously.

Looks like you guys have mitigated that. Is that the approach that's getting carried forward in the

Michael Amoroso
CEO, Precision

Absolutely correct, yeah. We learned a lot in our phase I. I mean, phase I by design is dose escalating and finding. This is really the first therapy. Because you're using cumulative editing to cut out the cccDNA, the virus at the liver, you do need those three administrations. Subsequent administrations of an LNP can absolutely cause an inflammatory or cytokine response. We've learned a lot about that and how to mitigate that. Cassie, why don't you talk the group through that?

Cassie Gorsuch
Chief Scientific Officer, Precision

Sure. One of the things that we learned in the phase I experience was that on repeat administrations, we saw an inflammatory response associated with the lipid, and we put in place some pretty practical, simple mitigations to help prevent that inflammatory response. So we extended the duration of the infusion from two hours to five hours. We also increased the amount of steroids that our participants were getting on the day of dosing. So they already were pre-prescribed steroids the day before and the day of. On that day of, we took it from 10 mg- 20 mg of dexamethasone, and then we also prophylactically provided a saline infusion with the drug infusion. And so those pretty easy to implement mitigations have continued to be effective, as you mentioned, for hypotension at that 0.4 mg per kg dose level.

We do not see hypotension at 0.4 with subsequent or first doses across any of the patients dosed under that current infusion protocol, and we will absolutely be taking that with us to our phase II study.

Michael Amoroso
CEO, Precision

The only other thing I would add, and Cassie might have said it is

when we first started, we had a full dosing regimen of two hours. We learned, as we have seen in all LNP programs, that first hour and the rate at what you infuse is super important. We have a totality of about a five-hour infusion, so we slow down the rate, simply take the steroids from 10 to 20 on the day of, push the saline prior to first administration and subsequent administrations, and we have not reproduced those hypotensive results. We feel really good, Debjit, about the 0.4 mg per kg going forward, that we really understand it.

Debjit Chattopadhyay
Analyst, Guggenheim

Another question on the tolerability side, the delayed increase in ALT that you

Michael Amoroso
CEO, Precision

That's the one. We had the one, yep.

Debjit Chattopadhyay
Analyst, Guggenheim

Is that viral clearance or is that cumulative tox of the LNP?

Michael Amoroso
CEO, Precision

Billion-dollar question. I think we feel really good with the LNP experts of the world that it's absolutely outside of the LNP window. We've seen it with other drugs. I'll let Cassie talk about the timeframe of maybe an LNP ALT/AST flare versus maybe an antiviral. I will say this. At all dose levels, even double what we're going to be going forward with, we've never seen bilirubin on any administration beyond the upper limit of normal. That's super important. We've had no concerns about liver function or any synthetic liver failures. You have some transaminitis that can be associated with LNP and/or a viral antiviral effect. Cassie, can you talk about what we saw in the one patient?

Cassie Gorsuch
Chief Scientific Officer, Precision

Yeah. I think in the context of lipid nanoparticle programs like ours, there's really two different flavors of transaminase elevations. One happens right after the LNP infusion and is very likely related to the lipid itself interacting with hepatocyte membranes. That would happen within the first week or two after the infusion. What we saw in one patient at our 0.4 mg go-forward dose level was a delayed transaminase elevation. It was three weeks after the LNP was infused, and based on LNP kinetics, that's outside the window of exposure. These transaminase elevations, as you point out, are interesting because they occur in the context of many different hep B studies and are often associated with antiviral effect in the liver.

We need to do more work to understand the etiology for this particular individual, but they are not unfamiliar in the context of hep B antiviral clinical studies.

Michael Amoroso
CEO, Precision

This, of course, was transient. ALT/AST peaked around the 300 marks, and of course, the patient returned to normal with no interventions. This could be a really important sign of antiviral activity, and we need to continue to track that and try to understand from different immune markers. We are looking at that. That will be important as we go forward.

Debjit Chattopadhyay
Analyst, Guggenheim

I want to get to DMD.

Michael Amoroso
CEO, Precision

Yes.

Debjit Chattopadhyay
Analyst, Guggenheim

One more question on the HBV side.

Michael Amoroso
CEO, Precision

Yes, sir.

Debjit Chattopadhyay
Analyst, Guggenheim

You disclosed the phase II plans, monotherapy plus the antisense. Could you talk about the baselines of what you're trying to enroll and what would be the ideal data set that you're hoping to get to?

Michael Amoroso
CEO, Precision

Yeah.

Debjit Chattopadhyay
Analyst, Guggenheim

Because this is a large market. I don't know if Precision by itself can commercialize something like this.

Michael Amoroso
CEO, Precision

Yeah. I will start off, and I'll ask Cassie to comment on it, and then we'll move to our other child, who we love, which is our DMD program, our function DMD program. First and foremost, the viral monotherapy, viral cure, as we've just talked about, eliminating cccDNA, undetectable HBV DNA, off therapies, all therapies, in the FDA guidance, number one, the gold standard. That is the goal of the monotherapy arm. We are the cccDNA drug. We target it, we eliminate it. You'll have three doses of PBGENE-HBV monotherapy at 0.4 mg per kg. You'll look at your pgRNA blood biomarker when present, and you will stop. You'll know when your intervention should be, course of time, whether it be two months to six months, we'll stop the nuke, and we'll look at viral cure rate. I'll remind everybody, it's at 0% today.

We've never been able to target the DNA level. Subsequently, we won't ignore the fact that a new step forward has been taken, and congratulations to our partners at GSK, more important to Pate for Patients. But 3% functional cure, suppression, not getting rid of virus, but suppression has been the gold standard of nucleoside analogs. Now it goes to 19% on the back of Bepi. And we know Bepi works best in patients with the lower viral load, and you can track S-antigen as that marker for lower viral load. That's where Bepi had the more robust results. What we are doing is, in the monotherapy arm, viral cure only, PBGENE three times. In the combo arm, we will look at PBGENE three times, and then Bepi will be dosed as per their new approved label. First and foremost, you'll look at viral cure.

If that cccDNA biopsy marker left anything behind, and by the way, that was an absolute percentage of 0.08%. But maybe somebody could reinfect. My guess is some immune systems will keep it at bay, some will get rid of it. Some potentially, I'm sorry, may not keep it at bay. If there's any pgRNA left over to make an HBV DNA, Bepi could be very complementary at cleaning up what was left in that less than 1%. Additionally, how do we potentially make Bepi better? Well, Bepi's approvable endpoint is functional cure. We know they don't get rid of the virus, and we know immunology is a big part of their mechanism. What you see there is, again, they work best when the viral load was lower. At a minimum, PBGENE eradicates more than 99% of the virus.

If you think about the patients that got the stop nukes in the Bepi trial, it was only about 24% of patients, and 19 held. That leaves 80% of patients behind. Many of the Bepi patients got the S low, but not enough low enough to stop the nukes. We think you might allow Bepi to have a much lower hurdle by first treating with PBGENE. Again, monotherapy arm, you'll look at viral cure, HBV DNA undetectable, line one in the FDA guidance.

In the combo arm, we'll look at that same line to see if any cleanup was needed for PBGENE, but we will also get the shot on goal to say, "Did we improve the functional cure rate of 19%?" Which frankly, we think we can do that for patients too, because we think we make Bepi, we put Bepi into their sweet spot when we lessen the viral burden. That is what the phase II will show. It's open label. You'll be able to see rolling results starting the second half of next year.

Debjit Chattopadhyay
Analyst, Guggenheim

Got it. One last one on this one before we do the DMD.

Michael Amoroso
CEO, Precision

You got it.

Debjit Chattopadhyay
Analyst, Guggenheim

Mostly to date, the trials have enrolled ex-U.S., right?

Michael Amoroso
CEO, Precision

Yeah

Debjit Chattopadhyay
Analyst, Guggenheim

What are the plans for U.S. trial? And let's move to DMD.

Michael Amoroso
CEO, Precision

Very similar. We go where the patients are. We will start in Asia. We are able to get fast traction there. We have a team already accruing. Then we will onboard Eastern Europe to start, and then the U.S. So it will be, you are going to probably see about an 80% Asian population to about a 20% targeted Caucasian population. Very similar to what you see in, for example, the B-WELL trials.

Debjit Chattopadhyay
Analyst, Guggenheim

Got it. Now back to your second child here.

Michael Amoroso
CEO, Precision

Yes.

Debjit Chattopadhyay
Analyst, Guggenheim

The one which is really close to my heart.

Michael Amoroso
CEO, Precision

Yes.

Debjit Chattopadhyay
Analyst, Guggenheim

This is not a gene augmentation program, right? What you are trying to get to is somewhat like an exon skipper, but on a permanent basis. Truncated DNA almost 80% the size of, not DNA, but truncated dystrophin almost 80% the size of normal. First patient, clean safety as of now. When do we see the data from the biopsy stuff, and by year end, how many do you plan to enroll?

Michael Amoroso
CEO, Precision

Sure. Cassie, maybe you can give a quick overview for the crowd of what the program is. Super important, to Debjit's point, taking back the body's native dystrophin. Second, you can really talk about three-quarters of the next four really important inflection points for DMD.

Cassie Gorsuch
Chief Scientific Officer, Precision

Sure. Yes, you are right. It sits between an exon skipper and a microdystrophin, and we think we take the best of both and improve on the limitations of both. PBGENE-DMD is a gene editing approach that is designed to excise a frequently mutated hotspot region of the dystrophin gene between exons 45 and 55. Unlike exon skippers, it can be broadly applicable, and it is a one-time treatment. So broadly applicable for the majority of patients. Many, many, many patients have mutations in this hotspot region. Not the case for exon skippers, obviously, that are mutation-specific, single exon-specific. On the microdystrophin side, very, very small protein that is produced, unknown function in humans. The protein that we make with our approach is near full-length dystrophin and known function in humans because it occurs in a subset of Becker patients with a very mild overall phenotype.

We think it improves upon the existing treatment landscape in really meaningful and important ways. So that is the approach for PBGENE-DMD. As you mentioned, we dosed our first patient in August at Arkansas Children's Hospital. All safety signs look good there. We shared that news recently. In terms of what is coming next, the first question is, how many patients by the end of the year? Our goal is to enroll part one of the study, that is our initial safety cohort, by the end of the year. So that is our three initial participants enrolled. We have patient two already enrolled, and we are screening patient three right now. So we are on track to complete that goal of enrolling those first three patients by the end of the year. This program is taking multiple biopsies from these kids. So baseline biopsies, three-month biopsy, and 12-month biopsy.

What we saw preclinically was that dystrophin expression grew in DMD diseased mice over time, which is why we are looking longitudinal in the clinical biopsies too. First half of next year, we expect to be able to share initial biopsy data from those initial patients on the study. That is the three-month biopsy data. More importantly, the 12-month biopsy data, where we will look to correlate it with functional outcomes, will come second half of next year. So, really excited for this program to continue advance. I do not know if you want to add anything else .

Michael Amoroso
CEO, Precision

Debjit, I know we're at time here. I just want to remind everybody that we were able to go out and bring in the back of the exciting data, both sets of data, $125 million to add to our preexisting cash position. That takes us through 2029, and more importantly, through into Q4 2029. More importantly, through the key late-stage clinical inflection points, a full phase II global HBV trial, known as ELIMINATE-B, as well as we've now fully raised to fund on our own pivotal for DMD. These late catalysts will have a data-rich year next year, in the next 12 months. That's both programs, HBV and DMD, and onward in 2028 and 2029 for our DMD pivotal. So, exciting inflection points to come.

Debjit Chattopadhyay
Analyst, Guggenheim

Well, congrats on the progress, and looking forward to a productive 2027.

Michael Amoroso
CEO, Precision

Thank you, sir. Great to see you.

Debjit Chattopadhyay
Analyst, Guggenheim

Appreciate it. Thank you so much, Cassie.